BRPI0906498A2 - Anticorpo ron e seus usos - Google Patents

Anticorpo ron e seus usos

Info

Publication number
BRPI0906498A2
BRPI0906498A2 BRPI0906498-2A BRPI0906498A BRPI0906498A2 BR PI0906498 A2 BRPI0906498 A2 BR PI0906498A2 BR PI0906498 A BRPI0906498 A BR PI0906498A BR PI0906498 A2 BRPI0906498 A2 BR PI0906498A2
Authority
BR
Brazil
Prior art keywords
ron antibody
ron
antibody
Prior art date
Application number
BRPI0906498-2A
Other languages
English (en)
Inventor
Hearther Huet
Veronique Bailly
Ellen Garber
Christilyn Graff
Steven Miklasz
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of BRPI0906498A2 publication Critical patent/BRPI0906498A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0906498-2A 2008-01-22 2009-01-22 Anticorpo ron e seus usos BRPI0906498A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2277908P 2008-01-22 2008-01-22
PCT/US2009/000376 WO2009094148A2 (en) 2008-01-22 2009-01-22 Ron antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0906498A2 true BRPI0906498A2 (pt) 2015-07-14

Family

ID=40901578

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906498-2A BRPI0906498A2 (pt) 2008-01-22 2009-01-22 Anticorpo ron e seus usos

Country Status (11)

Country Link
US (1) US20090226442A1 (pt)
EP (1) EP2245066A2 (pt)
JP (1) JP2011509687A (pt)
KR (1) KR20100106590A (pt)
CN (1) CN101977937A (pt)
AU (1) AU2009206724A1 (pt)
BR (1) BRPI0906498A2 (pt)
CA (1) CA2712697A1 (pt)
IL (1) IL207129A0 (pt)
MX (1) MX2010008025A (pt)
WO (1) WO2009094148A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
CA2785907A1 (en) * 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
PE20170687A1 (es) * 2010-01-28 2017-06-13 Glaxo Group Ltd Proteinas de enlace a cd127
EP3443981B1 (en) * 2010-06-29 2021-03-10 Centre National de la Recherche Scientifique (CNRS) Llt-1 antibodies with new functional properties
AR082194A1 (es) * 2010-07-06 2012-11-21 Aveo Pharmaceuticals Inc Anticuerpos anti-ron
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
SG11201404354UA (en) * 2012-02-17 2014-10-30 Seattle Genetics Inc ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
HK1220465A1 (zh) 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
KR102131371B1 (ko) * 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
CN110799211B (zh) 2016-09-08 2024-11-22 美国德州精准药靶有限公司 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
AU2018219887B2 (en) 2017-02-08 2024-08-15 Dragonfly Therapeutics, LLC Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CN110944661A (zh) 2017-02-20 2020-03-31 蜻蜓疗法股份有限公司 结合her2、nkg2d和cd16的蛋白质
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
CA3148611A1 (en) 2019-08-12 2021-02-18 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
JP7512394B2 (ja) 2020-05-06 2024-07-08 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
US7235523B2 (en) * 2001-04-13 2007-06-26 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
CA2450793A1 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US6867005B2 (en) * 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
WO2003065006A2 (en) * 2002-01-31 2003-08-07 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
CA2544074A1 (en) * 2003-10-24 2005-05-06 Esbatech Ag Method for the identification and/or validation of receptor tyrosine kinase inhibitors
CA2566647A1 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2006094073A2 (en) * 2005-03-02 2006-09-08 Acadia Pharmaceuticals Inc. Functional bioluminescence energy resonance transfer (bret) assay to screen, identify and characterize receptor tyrosine kinase ligands
CA2646508A1 (en) * 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
US7452985B2 (en) * 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
CL2008003449A1 (es) * 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.

Also Published As

Publication number Publication date
WO2009094148A2 (en) 2009-07-30
EP2245066A2 (en) 2010-11-03
MX2010008025A (es) 2010-08-04
WO2009094148A3 (en) 2010-01-14
JP2011509687A (ja) 2011-03-31
AU2009206724A1 (en) 2009-07-30
IL207129A0 (en) 2010-12-30
CN101977937A (zh) 2011-02-16
CA2712697A1 (en) 2009-07-30
US20090226442A1 (en) 2009-09-10
KR20100106590A (ko) 2010-10-01

Similar Documents

Publication Publication Date Title
BRPI0906498A2 (pt) Anticorpo ron e seus usos
BRPI1012321A2 (pt) anticorpos anti-vegf e seus usos
BRPI0910746A2 (pt) reticuladores e seus usos
BRPI0912198A2 (pt) anticorpos anti-fn14 e usos dos mesmos
BRPI1009455A2 (pt) anticorpos anti-c40 e usos dos mesmos
BRPI0921862A2 (pt) inibidores de raf e seus usos
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
HUE056626T2 (hu) Antitestkészítmény
BRPI0819909A2 (pt) anticorpos antimesotelina e usos dos mesmos
BRPI0908853A2 (pt) composto oligopeptídicos e seus usos
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
EP2371333A4 (en) THIN CLEANER ARTICLE
EP2358392A4 (en) ANTIBODY FORMULATION
EP2496707A4 (en) DEVELOPED ANTIBODY AGAINST TSLP
EP2482848A4 (en) Endoglin antibodies
PT2427212T (pt) Anticorpos anti-cd100 e métodos para utilização dos mesmos
FR2936364B1 (fr) Element magnetocalorique
PT3037529T (pt) Polipéptidos ph20 estendidos solúveis e suas utilizações
BRPI1006519A2 (pt) formulação de anticorpos
BRPI0913656A2 (pt) anticorpos anti-cdh3 marcados com marcador radioisótopo e usos dos mesmos
BRPI1010540A2 (pt) "anticorpos especéficos para dkk-1 e seus usos"

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.